Become A Featured Company

CureDots™ Look to Redefine How Animal Clinical Trials Are Conducted

Ryan Allway

September 14th, 2017

News, Top News

Animals are commonly used when testing drugs, vaccines, and biologics to determine the safety of the product before testing them on humans, according to the U.S. Food and Drug Administration. The focus of animal testing is to assess the drug’s nature, chemistry, and effects (pharmacology) and its potential damage to the body (toxicology) by measuring things like how it’s broken down in the body or how much is absorbed into the blood.

The standard technique for the consistent and precise delivery of drugs and biologics to animals is known as oral gavage (see Figure 1 below). But, the process is often not well-tolerated by the animal, may cause a great deal of stress, and could jeopardize the experiment since stress can cause a physiological response in an animal.

CURE Pharmaceutical (OTCQB: CURR) recently developed a more humane and effective technique for administering drugs to animals called CureDots™. Under the CureDots™ program, academic institutions may access punch-hole dot size versions of the company’s patented multilayer oral thin film (“OTF”) CureFilm Oral™ technology, which is ideal for pre-clinical testing with smaller animals like mice.

“Our goal is to support and accelerate promising translational academic research by making available precise dosage forms using our proprietary drug delivery technology,” said CURE Pharmaceutical Chief Business Officer Jessica Rousset. “We believe that using CureDots™ can become the new standard for humane preclinical research. We are looking forward to developing collaborative relationships with universities and research institutions.”

The new product will join the company’s growing line-up of innovative products centered around its oral thin film technology. These products include CureFilm Oral™ and CureFilm Transdermal™, which enables a variety of different products to be developed with less active ingredient, greater bioavailability, more precise dosing, and easier and more convenient administration of the therapeutic for patients.

Oral Thin Film Technology

CURE Pharmaceutical’s patented, multilayer oral thin film, CureFilm Oral™, can deliver medications to the tongue, cheek, or sublingual regions of the mouth, which enables medication to enter the blood stream through the gastrointestinal tract or through the buccal or sublingual mucosa. Formulations with this technology can match or improve the pharmacokinetic profile and the overall therapeutic index of an active pharmaceutical ingredient – or API.

In a third party study of its CureFilm Oral™ technology, researchers looked at the absorption of aspirin in rabbit models. They found that the oral thin film technology exhibited a faster onset and better bioavailability than a conventional tablet. Unlike liquid drops, oral thin films are also easier to transport and researchers can be sure that each ‘dot’ has an exact concentration of an API rather than having to be measured.

The company is capable of manufacturing CureDot™ products for researchers at scale through its top-rated manufacturing facility that is cGMP rated and FDA registered. The team’s robust and repeatable manufacturing process is designed to meet specific, measurable performance and product quality, while predetermined analytical testing and inspection points are built into the process to ensure high-quality and consistent results across all of its product lines.

Looking Ahead

CURE Pharmaceutical (OTCQB: CURR) is looking to redefine how researchers use animal models by introducing a more effective and human technique for administering drugs and biologics. A study published by the University of Southern California School of Pharmacy has already confirmed the effectiveness of the product. And with its fully-integrated operations, the company is already uniquely positioned to provide the new CureDot™ product at scale.

Investors may want to take a closer look at the stock given these developments. By penetrating the industry at the research level, the company will be well-positioned to expand into the commercial side of the business by establishing a wider presence.

For more information, visit the company’s website or investor presentation.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Network Partners

Follow Us on Social Media

LinkedIn

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading